Meriofert

Follicle-Stimulating Hormone, Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It treats infertility due to anovulation, supports assisted reproductive technology cycles, and replaces deficient hormones in hypogonadotropic hypogonadism.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Meriofert is distributed under controlled temperature conditions to preserve its biological activity.

Meriofert acts on the reproductive hormonal axis and is employed in several fertility‑related indications.

Infertility due to anovulation: stimulates follicular growth and estrogen production to induce ovulation in women who do not ovulate spontaneously. Assisted reproductive technology (ART): provides controlled ovarian stimulation for in‑vitro fertilisation cycles, enabling the development of multiple mature oocytes. Hypogonadotropic hypogonadism: replaces deficient pituitary gonadotropins, restoring normal ovarian function and facilitating conception in patients with hormonal insufficiency.

Meriofert may be associated with a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort, redness or swelling at the injection site. - Abdominal discomfort: transient bloating or mild pelvic pressure. - Nausea: occasional queasiness without vomiting. - Headache: mild to moderate tension‑type headache.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe abdominal distension, fluid accumulation, and possible thromboembolic complications. - Multiple pregnancy: increased risk of twins or higher order gestations. - Allergic reaction: anaphylaxis or severe hypersensitivity requiring immediate medical attention.

Prior to initiating Meriofert therapy, clinicians should evaluate patient history and monitor treatment closely.

- Monitor ovarian response: use serial ultrasound and estradiol measurements to adjust dose and avoid OHSS. - Adjust dose cautiously: titrate based on follicular development to minimize risk of excessive stimulation. - Contraindicated in pregnancy: do not administer to women who are already pregnant. - Avoid in known hypersensitivity: discontinue if allergic reactions to gonadotropins occur. - Use with caution in endocrine disorders: assess thyroid function and adrenal status before treatment. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other medications that affect ovarian stimulation or hemostasis, requiring careful management.

Major Interactions (Avoid): - Concurrent hCG therapy: may markedly increase risk of ovarian hyperstimulation syndrome. - Estrogen‑containing contraceptives: can alter hormonal response and reduce efficacy of stimulation. - Combined use with other gonadotropins: excessive hormone exposure may lead to severe OHSS.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase bleeding tendency at injection sites. - Systemic corticosteroids: can modify endogenous hormone levels and affect treatment outcomes.